Merck's MSD Animal Health Announces FDA Approval Of Expanded Label For BRAVECTO QUANTUM In Dogs

Merck Animal Health, a division of Merck & Co., Inc., announced that the FDA has approved an expanded label for BRAVECTO QUANTUM, allowing for the treatment and control of the Asian longhorned tick and Gulf Coast tick in dogs for 12 months with a single injection. This product, originally approved on July 10, 2025, also continues to be effective against adult fleas and several other tick infestations for varying durations. The approval enhances the product's market offering in the parasiticide treatment segment.